


Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. *N Engl J Med* 2010;362:1071-81.

Online appendix figure.

Mean daily lactulose use during the study in the ITT population. Dashed line represents the rifaximin group and solid line represents the placebo group. Summary statistics for lactulose use during the study are shown below the figure. One cup of lactulose is equal to 15 mL (10 g lactulose/15 mL).



	Rifaximin	Placebo
Mean daily lactulose use (\pm SD), cups/day	3.14 (\pm 2.096)	3.51 (\pm 2.592)
Mean rate of change in lactulose use (\pm SD), cups/day	0.0030 (\pm 0.03767)	0.0076 (\pm 0.10595)